Intraocular drug delivery platform
AssigneesSpyGlass Pharma, Inc., The Regents of the University of Colorado, a body corporate
InventorsGlenn Robert Sussman, Craig Alan Cable, II, Malik Y. Kahook
Life of this patent
Estimating the term…
Abstract
An intraocular drug delivery platform including a ring having an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass operably coupled to the anterior surface of the ring, and a second drug eluting mass operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.
Claims20
An intraocular drug delivery platform comprising:
- a ring comprising an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first haptic coupled to and extending outwards from the ring, a second haptic coupled to and extending outwards from the ring, a first drug eluting mass comprising a therapeutic agent operably coupled to the anterior surface of the ring, a second drug eluting mass comprising the therapeutic agent operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.
An intraocular drug delivery platform comprising:
- a ring comprising an anterior surface and a posterior surface opposite the anterior surface, a central aperture formed by the ring, a first drug eluting mass comprising a therapeutic agent operably coupled to the anterior surface of the ring, a second drug eluting mass comprising the therapeutic agent operably coupled to the anterior surface of the ring and positioned directly opposite of the first drug eluting mass.
Dependencies are inferred from the claim text.